R-etodolac + chlorambucil

R-etodolac + chlorambucil is a combination therapy investigated primarily for the treatment of chronic lymphocytic leukemia (CLL). R-etodolac (SDX-101) is the non-cyclooxygenase 2-inhibiting R-enantiomer of etodolac, a non-steroidal anti-inflammatory drug. Unlike standard etodolac, R-etodolac does not inhibit COX-2 and has demonstrated anti-tumor activity in CLL by inducing cytotoxicity and promoting apoptosis in malignant cells. Chlorambucil is an alkylating agent that interferes with DNA replication and transcription by cross-linking DNA strands, leading to cell cycle arrest and apoptosis. The combination was studied in phase 2 clinical trials for CLL but development was terminated. Mechanistically, the combination aims to enhance cytotoxic effects against leukemic cells through additive or synergistic induction of apoptosis via distinct pathways—R-etodolac through caspase-mediated mechanisms and chlorambucil via direct DNA damage[1][3][4][5][6].

Other names

R-etodolac + chlorambucilSDX-101 + chlorambucil